Metastatic Gastrointestinal Stromal Tumor

DrugDrug NameDrug Description
DB00619ImatinibImatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
DB08896RegorafenibRegorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumours. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April, 2017.
DrugDrug NameTargetType
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB08896RegorafenibCytochrome P450 3A4enzyme
DB08896RegorafenibUDP-glucuronosyltransferase 1-9enzyme
DB08896RegorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08896RegorafenibVascular endothelial growth factor receptor 1target
DB08896RegorafenibVascular endothelial growth factor receptor 2target
DB08896RegorafenibVascular endothelial growth factor receptor 3target
DB08896RegorafenibMast/stem cell growth factor receptor Kittarget
DB08896RegorafenibPlatelet-derived growth factor receptor alphatarget
DB08896RegorafenibPlatelet-derived growth factor receptor betatarget
DB08896RegorafenibFibroblast growth factor receptor 1target
DB08896RegorafenibFibroblast growth factor receptor 2target
DB08896RegorafenibAngiopoietin-1 receptortarget
DB08896RegorafenibDiscoidin domain-containing receptor 2target
DB08896RegorafenibHigh affinity nerve growth factor receptortarget
DB08896RegorafenibEphrin type-A receptor 2target
DB08896RegorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08896RegorafenibSerine/threonine-protein kinase B-raftarget
DB08896RegorafenibCytochrome P450 2C8enzyme
DB08896RegorafenibCytochrome P450 2C9enzyme
DB08896RegorafenibCytochrome P450 2B6enzyme
DB08896RegorafenibCytochrome P450 2C19enzyme
DB08896RegorafenibMitogen-activated protein kinase 11target
DB08896RegorafenibTyrosine-protein kinase FRKtarget
DB08896RegorafenibTyrosine-protein kinase ABL1target
DB08896RegorafenibMultidrug resistance protein 1transporter
DB08896RegorafenibATP-binding cassette sub-family G member 2transporter
DB08896RegorafenibUDP-glucuronosyltransferase 1-1enzyme
DrugDrug NamePhaseStatusCount
DB08875Cabozantinib2Recruiting1